Abstract
In this present work, 5-chloro-3-(substituted-benzylidene)indolin-2-one and 1-benzyl-5-chloro-3-(substitutedbenzylidene) indolin-2-one derivatives were synthesized and evaluated for their inhibitory activity against Src Family Kinases (SFKs) such as Fyn, Lyn and Hck. 5-Chloro-3-(substituted)indolin-2-ones (3a - 6a) and 1-benzyl-5-chloro-3- (substituted-benzylidene)indolin-2-ones (3b - 6b) were prepared by condensation of 5-chloro oxindole and 1-benzyl-5- chloro oxindole with the equivalent amount of aldehydes in EtOH in the presence of piperidine. Among all compounds, only 4a, 5b and 6b were found slightly active against Fyn with 13 - 16% inhibitions at 0.1 and 0.01 mM concentrations. Compounds did not exhibit any inhibitory potency against Lyn and Hck. Docking study of compounds was performed to evaluate receptor-binding properties of compounds and the results showed that the most active compound 6b binds into the active site of Fyn, which has similar binding mode with potent inhibitor PP2.
Keywords: Oxindole derivatives, Inhibition of SFKs, Synthesis, Selectivity, Docking, Activity.
Letters in Drug Design & Discovery
Title:Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Volume: 10 Issue: 8
Author(s): Zühal Kilic-Kurt, Arzu Onay-Besikci and Sureyya Olgen
Affiliation:
Keywords: Oxindole derivatives, Inhibition of SFKs, Synthesis, Selectivity, Docking, Activity.
Abstract: In this present work, 5-chloro-3-(substituted-benzylidene)indolin-2-one and 1-benzyl-5-chloro-3-(substitutedbenzylidene) indolin-2-one derivatives were synthesized and evaluated for their inhibitory activity against Src Family Kinases (SFKs) such as Fyn, Lyn and Hck. 5-Chloro-3-(substituted)indolin-2-ones (3a - 6a) and 1-benzyl-5-chloro-3- (substituted-benzylidene)indolin-2-ones (3b - 6b) were prepared by condensation of 5-chloro oxindole and 1-benzyl-5- chloro oxindole with the equivalent amount of aldehydes in EtOH in the presence of piperidine. Among all compounds, only 4a, 5b and 6b were found slightly active against Fyn with 13 - 16% inhibitions at 0.1 and 0.01 mM concentrations. Compounds did not exhibit any inhibitory potency against Lyn and Hck. Docking study of compounds was performed to evaluate receptor-binding properties of compounds and the results showed that the most active compound 6b binds into the active site of Fyn, which has similar binding mode with potent inhibitor PP2.
Export Options
About this article
Cite this article as:
Kilic-Kurt Zühal, Onay-Besikci Arzu and Olgen Sureyya, Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases, Letters in Drug Design & Discovery 2013; 10 (8) . https://dx.doi.org/10.2174/15701808113109070023
DOI https://dx.doi.org/10.2174/15701808113109070023 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery β-lactam Functionalized Poly(isoprene-b-ethylene oxide) Amphiphilic Block Copolymer Micelles as a New Nanocarrier System for Curcumin
Current Nanoscience CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Current Pharmaceutical Design Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation
Medicinal Chemistry TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer
Current Medicinal Chemistry Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Opinion Paper: Microfluidics Technique to Revolutionize the Drug Delivery Field: Current Developments and Applications
Current Drug Delivery Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
Clinical Cancer Drugs CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets